Enter Note Done
Go to previous page in this tab
Event
  • Scientific Session
  • Bookmark Icon
  • Clearing the Canopy: Advancing Predictive Confidence in Respiratory In Vitro NAMs Through Model Characterization
  • Schedule
    Notes
  • Stars at Night Ballroom B4‚ Convention Center
    Set Timezone


Chair: Erin Huber, RTI International
Co-Chair: Emily Reinke, General Dynamics Corporation

Primary Endorser: In Vitro and Alternative Methods Specialty Section


Endorser(s): Exposure Specialty Section


Endorser(s): Inhalation and Respiratory Specialty Section


With increasing regulatory and scientific momentum in the past year toward the use of New Approach Methodologies (NAMs), human-based in vitro models are rapidly expanding as alternatives to replace animal testing for evaluating inhaled toxicants and predicting human health outcomes and disease manifestation. While organotypic in vitro models from the liver and skin have gained broader regulatory acceptance and integration into validated NAM platforms, primary cell-based respiratory in vitro NAMs have faced slower adoption due to challenges surrounding model characterization, standards in exposure methodologies, and data interpretation. Commonly used in toxicological assessments for inhaled test article evaluations, differentiated primary human bronchial epithelial cell (dpHBEC) air-liquid interface (ALI) cultures display increased in vivo relevance by recapitulating key features of the bronchial epithelium, including mucin-producing goblet cells and beating cilia. However, this model only represents one cell type in the in vivo respiratory microenvironment. The complexity of modeling the lung in vitro poses challenges including the interplay and crosstalk between cell types such as epithelial cells, fibroblasts, and immune cells. Additional challenges exist from exposure delivery and dosimetry considerations of test articles, repeated exposure durability, and sample size estimates to account for donor-based biological variability. Primary human in vitro models display inter-individual variability capturing the heterogenous responses to toxicant exposures within the population which increases their predictive capacity and relevance to human exposures. While biological heterogeneity enhances human relevance and predictive strength, technical variables including culture conditions, cell culture media composition, and exposure methodologies can strongly influence study outcomes thus limiting reproducibility, interpretation, and regulatory confidence. As respiratory NAM models and study design become more complex, there is a need for stronger model characterization and harmonization among NAM-users is needed to improve the understanding of how experimental design influences endpoint response and translational utility. Current efforts are focused on characterizing and harmonizing methodologies in respiratory in vitro NAM models using empirical evidence to push the norm of current study design and exposure paradigms in the field to more in vivo-relevant and biologically complex modalities for real-world human exposure and health outcomes.


This session will highlight how study design and in vitro model characterization shape data interpretation in complex respiratory in vitro systems. The first speaker will begin with a presentation discussing variability in primary ALI culture morphology and performance driven by common culture conditions and culture maintenance medium. The second speaker will provide emerging considerations for ALI study design harmonization, including direct liquid application versus ALI exposure approaches, dosimetry considerations, and factors that influence reproducibility and interpretability of respiratory in vitro toxicology study data. The final speaker will discuss primary human in vitro model complexity, including cell-type specific effects, along with response trajectory evaluation in common inhalation in vitro endpoints when using single or repeated exposure paradigms. These experts will then be convened in a panel discussion focused on current barriers and future opportunities including harmonization across exposure methodologies, extrapolation of acute in vitro outcomes to predict chronic toxicity, and strategies to strengthen confidence, interpretation, and regulatory acceptance of primary human respiratory in vitro models. By the end of this session, participants will gain a stronger understanding of how model design, exposure methodology, and biological complexity influence the interpretation, predictive capacity, and translational relevance of respiratory in vitro NAMs in human health assessments.

Session and Activity Type
Presentations